ImmuCell Corporation (ICCC) is a Biotechnology company in the Healthcare sector, currently trading at $7.73. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ICCC = $20.54 (+165.7% from the current price, the stock appears undervalued).
Valuation: ICCC trades at a trailing Price-to-Earnings (P/E) of -63.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.17.
Financials: revenue is $28M, +16.7%/yr average growth. Net income is $1M (loss), growing at -5.7%/yr. Net profit margin is -3.8% (negative). Gross margin is 41.4% (+0.2 pp trend).
Balance sheet: total debt is $13M against $27M equity (Debt-to-Equity (D/E) ratio 0.49, conservative). Current ratio is 4.26 (strong liquidity). Debt-to-assets is 31%. Total assets: $43M.
SharesGrow 7-Criteria breakdown: Value 87/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 39/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).
